BIOENHANCEMENT EFFECT OF PIPERINE AND GINGER OLEO RESIN ON THE BIOAVAILABILITY OF ATAZANVIR

  • Swati Prakash Guru Ghasidas Vishwavidyalaya (Central University)
  • Pankaj Kherde Guru Ghasidas Vishwavidyalaya (Central University)
  • Vinod Rangari S. L. T. Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (Central University), Koni, Bilaspur 495009, Chhattisgarh, India

Abstract

Objective: The present study was undertaken to investigate the bioavailability enhancing effect of the natural bioavailability enhancers, piperine and ginger oleoresin on the antiretroviral drug atazanvir in combination with ritonavir.

Methods: Sprague-Dawley rats of either sex, were used for the bioavailability studies of ATV and RTV in combination of Piperine. All the drugs were administered orally in the form of suspension to the animals. The bioavailability studies were performed by determination of the drugs concentration in plasma by the HPLC.

Results: The bioavailability of atazanvir was found to be significantly increased in combination with piperine and ginger oleoresin. However, piperine has demonstrated better effect as compared to ginger oleoresin in all the groups. Piperine (30 mg/kg) when administered in combination with atazanvir (ATV), has shown to increase the bioavailibility of both the doses of ATV (6.5 mg/250 gm) and ATV (3.25 mg/250 gm) significantly as compared to the conventional doses.

Conclusion: Results of the investigation proves a significant bioavailability enhancement effect of piperine and ginger oleo resin on atazanavir in lower doses as well as in the absence of rotinavir. These studies places piperine as a mode of increasing activity of atazanvir.

 

Keywords: Atazanvir, Ritonavir, Bioavailabilty enhancers, Piperine, Ginger oleoresin

Downloads

Download data is not yet available.

References

1. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-90.
2. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996;51:701–12.
3. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1992;2484–8.
4. Lea AP, Faulds D. Ritonavir. Drugs 1996;52:541–6.
5. Li Xiaoling, William KC. Transport metabolism and elimination mechanisms of anti-HIV Agents. Adv Drug Delivery Rev 1999;39:81-103.
6. Shimpi S. Bioequivalence study recommendation for atazanavir sulfate capsules by US FDA and a contrary view. Open Access Scientific Reports 2012;8:388-95.
7. Lucia M, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquired Immune Defic Syndr 2005;39:635–7.
8. Perloff E, Duan S, Skolnik P, Greenblatt D, von Moltke L. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005;33:764–70.
9. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel. J Am Med Assoc 2008;300:555-70.
10. Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. New Microbiol 2007;30:79-88.
11. Rangari Vinod D, Dumbre Rahul K, Dumbre Manisha R. HIV-AIDS and Bioactive Natural Products, Studium Press: Llc, Houston, Texas, USA; 2009. p. 4-6.
12. Oldfield V, Plosker GL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2006;66:1275–99.
13. Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents 2005;26:88–91.
14. Atal CK. A breakthough in drug bioavailability-A clue from age old wisdom of Ayurveda. IDMA Bulletin 1979;10:483-4.
15. Zutshi RK, Singh R, Zutshi U, Johi RK, Atal CK. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. J Assoc Physicians India 1985;33:223-34.
16. Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 1985;232:258-62.
17. Gulam Q, Bedi K, Johi R, Tikoo M, Tikoo A, Sharma S, et al. Bioavailibility enhancing activity of Zingiber officinale Linn and its extracts/fractions thereof. US Patent; 2003.
18. Al-Amin ZM, Thomson M, Al-Qattan KK, Peltonen-Shalaby R, Ali M. Antidiabetic and hypolipidaemic properties of ginger (Zingiber officinalis) in streptozotocin induced diabetic rats. Br J Nutr 2006;4:660-6.
19. Setty Venkata, Kullai D, Santhosh Rao, Narasimha Kumar Sanjeeva, Martin Charles. Preliminary phytochemical screening and antidiabetic activity of Zingiber officinale rhizomes. Int J Pharm Life Sci 2011;2:1287-92.
20. Lledo-Garcia R, Nacher A, Prats-Garcia L, Casabo VG, Merino-Sanjuan M. Bioavailibility and pharmacokinetic model for Ritonavir in the rat. J Pharm Sci 2007;96:633-43.
21. Ali B, Amin S, Ahmad J, Ali Abuzer, Ali Mohd, Mir SR. Bioavailibility enhancement studies of amoxicillin with Nigella. Indian J Med Res 2012;135:555-9.
22. Zaveri M, Patel K, Patel S. Screening of some selected plants for CYP3A inhibition and bioavailibility enhancement. Adv Res Pharm Biol 2011;1:19-27.
Statistics
353 Views | 708 Downloads
How to Cite
Prakash, S., P. Kherde, and V. Rangari. “BIOENHANCEMENT EFFECT OF PIPERINE AND GINGER OLEO RESIN ON THE BIOAVAILABILITY OF ATAZANVIR”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 11, Aug. 2015, pp. 241-5, https://innovareacademics.in/journals/index.php/ijpps/article/view/5575.
Section
Original Article(s)